Multiple label expansions of premium-priced agents and the launch of four novel therapies will fuel the significant growth of the multiple myeloma market over the ten-year forecast period. The generic erosion expected for lenalidomide, the patient share and sales leader of 2015 in the multiple myeloma space, as well as the generic erosion of bortezomib, pomalidomide and thalidomide will temper the overall growth of this market. Untapped clinical and commercial potential remains in multiple myeloma for therapies with improved efficacy and for agents positioned in patient segments that are currently underserved.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: 22 country-specific interviews with leading hematological oncologists and survey data from 30 physicians in each of the major markets who treat at least 68 multiple myeloma patients per year.
Epidemiology: Diagnosed incident cases of multiple myeloma, diagnosed incident cases of monoclonal gammopathy of undetermined significance (MGUS).
Population segments in market forecast: Drug-treatable patients with symptomatic myeloma including first- (transplant-eligible and transplant-ineligible), second-, third-, and fourth-line segments.
Emerging therapies: Phase I and II: 28 drugs; Phase III: 5 drugs; preregistration: 1 drug; registered: 0 drugs.